Novartis AG

About

Novartis AG is a Swiss multinational pharmaceutical company listed on the SIX Swiss Exchange (NOVN) and, as American Depositary Shares, on the New York Stock Exchange (NVS). It was formed in 1996 from the merger of Ciba-Geigy and Sandoz and is headquartered in Basel. It is included here as a major industry player whose portfolio intersects with aging biology rather than as a dedicated longevity company. Two Novartis assets have probed core aging pathways in humans. The interleukin-1-beta antibody canakinumab (Ilaris) was tested in the CANTOS trial, which linked inhibition of this inflammaging pathway to fewer cardiovascular events and a dose-dependent reduction in cancer mortality. The mTOR inhibitor everolimus (RAD001) improved the immune response to influenza vaccination in older adults, providing early human evidence that mTOR inhibition can partially reverse immunosenescence. Discovery is led by Novartis Biomedical Research.

Rating breakdown

Aggregate 70/100 · rank #3 in the commercial table full ratings →

Expand a signal to see what contributes to it.

Key outputs

• product Canakinumab (Ilaris): interleukin-1-beta antibody; the CANTOS trial linked inhibition of the inflammaging pathway to fewer recurrent cardiovascular events and a dose-dependent reduction in cancer mortality ↗ 2017
• product Everolimus (RAD001): mTOR inhibitor shown to enhance influenza-vaccine response in older adults, early human evidence that mTOR inhibition can partially reverse immunosenescence ↗ 2014
• publication Effect of interleukin-1-beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from CANTOS (Lancet): inhibiting the inflammaging pathway reduced incident lung cancer and lung-cancer mortality ↗ 2017

Registered clinical trials

130 trials list this organisation as lead sponsor ClinicalTrials.gov ↗

• A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates ↗ NOT_YET_RECRUITING · 2026-09-15
• Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis. ↗ RECRUITING · 2026-08-15
• HJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Pressure and Patients With Hypertension ↗ PHASE1 · RECRUITING · 2026-07-02
• Integrating Point of Care Testing (POCT) For Newborn Screening and Early Care for Sickle Cell Disease in Yopougon, Côte d'Ivoire ↗ PHASE4 · NOT_YET_RECRUITING · 2026-04
• Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2) ↗ PHASE2 · RECRUITING · 2026-02-12
• Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population ↗ RECRUITING · 2025-12-17
• A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease ↗ PHASE2 · RECRUITING · 2025-11-03
• Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers ↗ PHASE1 · RECRUITING · 2024-10-15

Showing 8 of 130 registered trials.

Financial

Market cap

USD 277.45B · NVS (2026-09-29)

Key people

Research fields

Links